When it comes to repairing aneurysms after an aneurysmal subarachnoid hemorrhage (aSAH), sooner might not always be better—at least in terms of survival and recovery. That’s the key takeaway from a sweeping systematic review published this month, which sifted through studies comparing outcomes across treatment windows ranging from less than 6 hours to more than 15 days after symptom onset.
The clearest benefit of early aneurysm repair was a reduction in the rate of pretreatment rebleeding, especially in patients who remained untreated or faced substantial delays. However, the review, led by Fiore TFO and colleagues, found no consistent independent link between how quickly aneurysm repair was performed and either mortality or functional outcomes. In fact, the certainty of evidence regarding mortality was considered “very low,” hampered by bias, inconsistent results, and imprecise data.
Nuanced Outcomes, More Questions Than Answers
Experts have stopped short of recommending any sweeping changes to current clinical practice. The consensus: current guidelines urging repair “as early as feasible” are still appropriate until higher-quality, multicenter studies can clarify the real impact of timing. This means that, for now, decisions about when to intervene should be tailored to each patient—taking into account aneurysm characteristics, patient age, and overall health—rather than a rigid timeline.
Meanwhile, research into unruptured intracranial aneurysms, which affect an estimated 3% to 5% of the global population, suggests that immediate intervention does not always provide a clear advantage over careful monitoring. In these cases, factors like the aneurysm’s size, shape, and wall irregularity, as well as patient-specific risks, are now front and center in treatment planning. The latest clinical trials reinforce that personalized care—balancing anatomical and hemodynamic factors against surgical risks—remains the cornerstone of modern neurovascular medicine.
What’s Next for Patients and Providers?
The new review underscores a crucial point: while rapid aneurysm repair after aSAH can lower the danger of rebleeding, it’s not a magic bullet for reducing deaths or disability. As the field moves forward, experts are calling for robust, prospective multicenter studies that use advanced statistical approaches to untangle the true effects of treatment timing—free from confounding and survivor bias. Until then, individualized therapy remains the guiding principle for patients and providers alike.
